Literature DB >> 22453736

Renovascular hypertension--is it fibromuscular dysplasia or Takayasu arteritis.

Kjell Tullus1.   

Abstract

Renovascular hypertension (RVH) can be caused by many different diseases, with the most common being fibromuscular dysplasia (FMD) and Takayasu arteritis (TA). A strikingly different diagnostic pattern is seen in children with RVH from different parts of the world. In Europe and North America, these children are mainly diagnosed as having FMD while in Asia and South Africa they will most often get a diagnosis of TA. When comparing the clinical diagnosis for FMD and TA, it becomes obvious that there is a great deal of overlap between the definitions of these two conditions. Different ways to come to the most accurate diagnosis using imaging of the blood vessel wall and positron emission tomography (PET) will be discussed. How an accurate diagnosis should influence the treatment of the children with these conditions will also be addressed.

Entities:  

Mesh:

Year:  2012        PMID: 22453736     DOI: 10.1007/s00467-012-2151-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  43 in total

1.  Angiographic features of 26 children with Takayasu's arteritis.

Authors:  Mignon McCulloch; Savvas Andronikou; Elizabeth Goddard; Paul Sinclair; John Lawrenson; Simone Mandelstam; Steve J Beningfield; Alastair J J W Millar
Journal:  Pediatr Radiol       Date:  2003-02-05

2.  Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu's arteriopathy.

Authors:  K Ishikawa
Journal:  J Am Coll Cardiol       Date:  1988-10       Impact factor: 24.094

Review 3.  Diagnosis, management, and future developments of fibromuscular dysplasia.

Authors:  Jeffrey W Olin; Brett A Sealove
Journal:  J Vasc Surg       Date:  2011-01-13       Impact factor: 4.268

Review 4.  PET in vasculitis.

Authors:  Daniel Blockmans
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

5.  Renal FMD may not confer a familial hypertensive risk nor is it caused by ACTA2 mutations.

Authors:  Stephen D Marks; Ambrose M Gullett; Eileen Brennan; Kjell Tullus; Graciana Jaureguiberry; Enriko Klootwijk; Horia C Stanescu; Robert Kleta; Adrian S Woolf
Journal:  Pediatr Nephrol       Date:  2011-05-08       Impact factor: 3.714

6.  Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate.

Authors:  Fumiko Tanaka; Atsushi Kawakami; Nozomi Iwanaga; Mami Tamai; Yasumori Izumi; Kouichiro Aratake; Kazuhiko Arima; Makoto Kamachi; Hideki Nakamura; Mingguo Huang; Hiroaki Ida; Tomoki Origuchi; Katsumi Eguchi
Journal:  Intern Med       Date:  2006-04-03       Impact factor: 1.271

7.  Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis.

Authors:  Samuel K Shinjo; Rosa M R Pereira; Vivian A P Tizziani; Ari S Radu; Maurício Levy-Neto
Journal:  Clin Rheumatol       Date:  2007-02-28       Impact factor: 2.980

8.  Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.

Authors:  Gary S Hoffman; Peter A Merkel; Richard D Brasington; Deborah J Lenschow; Patrick Liang
Journal:  Arthritis Rheum       Date:  2004-07

Review 9.  Renovascular hypertension in children.

Authors:  Kjell Tullus; Eileen Brennan; George Hamilton; Rozanne Lord; Clare A McLaren; Stephen D Marks; Derek J Roebuck
Journal:  Lancet       Date:  2008-04-26       Impact factor: 79.321

10.  Pediatric renovascular hypertension: a thirty-year experience of operative treatment.

Authors:  J C Stanley; G B Zelenock; L M Messina; T W Wakefield
Journal:  J Vasc Surg       Date:  1995-02       Impact factor: 4.268

View more
  12 in total

1.  Management of the renovascular disease in children with Takayasu arteritis.

Authors:  Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-05-16       Impact factor: 3.714

2.  Pitfalls in diagnosing and treating children with renal artery hypertension.

Authors:  Kjell Tullus; Derek Roebuck
Journal:  Pediatr Nephrol       Date:  2013-03-28       Impact factor: 3.714

3.  Pitfalls in diagnosing and treating children with renal artery hypertension: author's reply.

Authors:  Preeti Shanbag; Sanjeevani Masavkar
Journal:  Pediatr Nephrol       Date:  2013-04-07       Impact factor: 3.714

4.  Remedial operations for failed endovascular therapy of 32 renal artery stenoses in 24 children.

Authors:  Jonathan L Eliason; Dawn M Coleman; Enrique Criado; David B Kershaw; Neal B Blatt; David M Williams; Narasimham L Dasika; Kyung J Cho; James C Stanley
Journal:  Pediatr Nephrol       Date:  2015-12-01       Impact factor: 3.714

5.  Childhood-onset Takayasu Arteritis.

Authors:  Florence A Aeschlimann; Marinka Twilt; Rae S M Yeung
Journal:  Eur J Rheumatol       Date:  2020-02

Review 6.  Interventions for pediatric renovascular hypertension.

Authors:  Kevin E Meyers; Anne Marie Cahill; Christine Sethna
Journal:  Curr Hypertens Rep       Date:  2014-04       Impact factor: 5.369

7.  Aortic bypass and bilateral renal autotransplantation for mid-aortic syndrome.

Authors:  Anna Poupalou; Rémi Salomon; Younes Boudjemline; Emma Allain-Launay; Yves Aigrain; Christophe Chardot
Journal:  Pediatr Nephrol       Date:  2013-04-13       Impact factor: 3.714

8.  Differences between the pediatric and adult presentation of fibromuscular dysplasia: results from the US Registry.

Authors:  Rebecca Green; Xiaokui Gu; Eva Kline-Rogers; James Froehlich; Pamela Mace; Bruce Gray; Barry Katzen; Jeffrey Olin; Heather L Gornik; Ann Marie Cahill; Kevin E Meyers
Journal:  Pediatr Nephrol       Date:  2015-11-02       Impact factor: 3.714

Review 9.  Renovascular hypertension in pediatric patients: update on diagnosis and management.

Authors:  Juliana Lacerda de Oliveira Campos; Letícia Bitencourt; Ana Luisa Pedrosa; Diego Ferreira Silva; Filipe Ji Jen Lin; Lucas Teixeira de Oliveira Dias; Ana Cristina Simões E Silva
Journal:  Pediatr Nephrol       Date:  2021-04-13       Impact factor: 3.714

Review 10.  An Update on Childhood-Onset Takayasu Arteritis.

Authors:  Florence A Aeschlimann; Rae S M Yeung; Ronald M Laxer
Journal:  Front Pediatr       Date:  2022-04-13       Impact factor: 3.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.